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The mRNA for leukemia inhibitory factor (LIF), a neuroimmune
signaling molecule, is elevated during skin inflammation pro-
duced by intraplantar injection of complete Freund’s adjuvant
(CFA). Moreover, although LIF knock-out mice display normal
sensitivity to cutaneous mechanical and thermal stimulation
compared with wild-type mice, the degree of CFA-induced
inflammation in mice lacking LIF is enhanced in spatial extent,
amplitude, cellular infiltrate, and interleukin (IL)-1b and nerve
growth factor (NGF) expression. Conversely, local injection of
low doses of recombinant LIF diminishes mechanical and ther-
mal hypersensitivity as well as the IL-1b and NGF expression
induced by CFA. These data show that upregulation of LIF
during peripheral inflammation serves a key, early anti-
inflammatory role and that exogenous LIF can reduce inflam-
matory hyperalgesia.
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Leukemia inhibitory factor (LIF) is a neuropoietic cytokine
involved in both the neural and immune responses to injury. Its
levels are increased in a variety of animal and human inflamma-
tory conditions (Perry et al., 1987; Alexander et al., 1994; Brown
et al., 1994; Ulich et al., 1994; Benigni et al., 1996; Heyman et al.,
1996; Weinhold and Ruther, 1997). Administration of LIF can
suppress inflammatory signs in some cases (Alexander et al.,
1994), for instance after intratracheal lipopolysaccharide-induced
inflammation (Ulich et al., 1994). LIF also increases corticoste-
rone levels via the hypothalamo–pituitary–adrenal axis (Baba et
al., 1998). Other evidence suggests, however, that it can also act as
a proinflammatory cytokine. Exogenously added LIF induces
acute phase protein expression (Ryffel, 1993; Mehlen et al., 1997)
and stimulates the production of proinflammatory cytokines and
monocyte chemoattractants (Alexander et al., 1994; Paglia et al.,
1996; Shimon et al., 1997). Moreover, passive immunization
against LIF protects mice against the lethal effects of endotoxin
and blocks endotoxin-induced increases in serum interleukin-1
(IL-1) and IL-6 (Block et al., 1993), and injection of high con-
centrations of LIF into skin or joints can induce swelling and
leukocyte invasion (Carroll et al., 1995; McKenzie et al., 1996).
In the nervous system, LIF mRNA levels dramatically increase
soon after injury (Patterson, 1994; Kurek et al., 1996; Banner et
al., 1997), and experiments with LIF null mutant mice demon-
strate that LIF is required for some of the striking changes in
neuronal gene expression that are characteristic of the injury
response (Rao et al., 1993; Corness et al., 1996; Sun and Zig-
mond, 1996). Lack of LIF can also lead to premature neuronal
death (Sendtner et al., 1996) and a diminished rate of immune
cell influx after peripheral nerve injury (Patterson et al., 1997).
LIF and its receptors (gp130) are abundantly expressed in pitu-
itary cells, and LIF acts in a paracrine manner to regulate
adrenocorticotrophin and growth hormone release (Lotz et al.,
1992; Waring et al., 1992; Szepietowski et al., 1997).
Thus, although LIF appears to be a central regulator of inflam-
matory events and their interaction with the nervous system,
there is contradictory evidence whether this cytokine is pro-
inflammatory or anti-inflammatory. To help clarify these issues
and to further probe interactions between the nervous and im-
mune systems during the injury response, we have used both LIF
knock-out mice and LIF injections in a well characterized, local
inflammatory pain model, the intraplantar injection of complete
Freund’s adjuvant (CFA) (Stein et al., 1988; Woolf et al., 1994,
1996; Safieh-Garabedian et al., 1995).
MATERIALS AND METHODS
All animal procedures conformed with the requirements of either the
British Home Office Animal Licensing Inspectorate or the Caltech
Research Animal Care Committee.
Inflammation in rats. Experiments were performed on adult male
Sprague Dawley rats (200–250 gm). A unilateral, acute inflammatory
lesion was produced by an injection into the plantar surface of the
hindpaw, under halothane anesthesia (2%), of 100 ml of CFA [1 mg/ml
Mycobacterium tuberculosis (H37Ra, ATCC 25177, in 0.85 ml of paraffin
oil and 0.15 ml of mannide monooleate; Sigma, St. Louis, MO)]. Thermal
and mechanical sensitivity were tested as described previously in detail
(Safieh-Garabedian et al., 1995; Woolf et al., 1996). Foot withdrawal on
exposure to a hot plate (50°C) was used as an index of thermal sensitivity,
whereas the mechanical threshold for eliciting a flexion withdrawal
response was measured in grams, using calibrated monofilament Von
Frey hairs (4.1–72 gm) as an index of mechanical sensitivity. Von Frey
hairs were applied three times (0.5 Hz) at a right angle to the dorsum of
the foot in ascending order of force until a withdrawal response was
elicited on all three occasions. The order was then reversed, and lower-
force hairs were applied. The threshold was defined as the lowest force
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hair that elicited a clear withdrawal response on each of the three
applications. Paw diameters in millimeters were measured under termi-
nal pentobarbital anesthesia (500 mg/kg, i.p.) using a micrometer gauge
(Stanley) applied across the dorsoventral plane of the hindpaw in its
midposition.
LIF null mutant mice. LIF-deficient mutant mice (Stewart et al., 1992)
were maintained by mating within the original colony of the mutant
strain or by back-crossing with the C57Bl6 parental strain. All of the data
reported here on mutant mice come from the former matings. Null
mutants were produced by mating heterozygotes or by mating null males
with heterozygote females. Nulls, heterozygotes, and wild-type (WT)
mice were compared as littermates. A PCR-based method was used to
determine the genotype of the mice. Genomic DNA was isolated from
tail biopsies and subjected to PCR amplification. Two DNA fragments
were coamplified: a 192 bp LIF gene fragment and a 541 bp neomycin
gene fragment. LIF WT mice contained only the LIF product (192 bp),
the heterozygotes had both bands (192 and 541 bp), and the LIF-deficient
mice had only the larger fragment (541 bp).
Inflammation in mice. CFA induced inflammation in LIF 2/2 and 1/1
mice was produced as above, except that only 20 ml of CFA was injected.
Mechanical sensitivity was measured using Von Frey hairs as above, and
paw diameter was also measured as described above. The CFA injections
into the mice were all made together at one sitting, and the tester was
blinded to the genotype of the animals. Inflammatory cell infiltration was
studied in paraformaldehyde-fixed, hematoxylin and eosin-stained skin
sections. Cell types were quantified by counting neutrophils and mast
cells from three animals of each genotype (three sections per animal).
The number of polymorphonuclear neutrophils was determined by
counting the number of cells with multilobed nuclei in a representative
100-mm-wide band from the outer edge of the epidermis to the inner
edge of the dermis. Only cells with more than one nucleus per cell were
taken as positive. Mast cells were quantified in a similar manner, count-
ing only those cells that were of the appropriate size and contained
obvious granules.
LIF mRNA measurements. Rat footpad skin was removed under deep
terminal pentobarbital anesthesia, and total RNA was extracted by the
acid–phenol method and RNase protection performed as described pre-
viously (Banner and Patterson, 1994). The intensity of the radioactive
signal emitted by the LIF-protected fragment was compared with the
glyceraldehyde phosphate dehydrogenase (GAPDH)-protected fragment
as an internal control for the steady-state amount of RNA, and the values
were expressed in arbitrary units. GAPDH mRNA was found not to
change with injury.
IL-1 and NGF measurements. Under deep terminal pentobarbital an-
esthesia, samples of either rat or mouse hindpaw skin, sciatic nerve, and
L4 and L5 dorsal root ganglia were dissected, weighed, and frozen on dry
ice. The tissue was used for determination of IL-1b and NGF by ELISA,
as described previously (Safieh-Garabedian et al., 1995). Results are
expressed as nanograms per hindpaw to account for changes in weight of
inflamed skin.
LIF administration. Recombinant human LIF (Preparation 93/562, 1
mg 5 10,000 U; National Institute for Biological Standards and Control)
was dissolved in saline at concentrations of 100 or 1000 ng/ml and
injected into the rat hindpaw under halothane anesthesia (2%) in a
volume of 100 ml.
Statistical analysis. All results are presented as mean 6 SEM. Differ-
ences were calculated using Student’s or Welch’s t test, ANOVA followed
by Dunnet’s multiple-comparison test, or the Mann–Whitney U test,
where appropriate.
RESULTS
LIF mRNA levels in inflamed skin
Six hours after induction of acute inflammation in the rat hind-
paw by intraplantar injection of CFA, LIF mRNA levels were
measured by an RNase protection assay and expressed as a ratio
with GAPDH mRNA. This cytokine is elevated in the inflamed
skin at this time (4.1 6 1.8 ipsilateral, 2.8 6 1.1 contralateral,
from naive levels of 1.0; LIF/GAPDH 6 SEM; n 5 4), with a
trend to a further increase at 48 hr (5.7 6 2.1 ipsilateral, 1.4 6 0.3
contralateral). A smaller, bilateral change occurred in the sciatic
nerve (2.4 6 1.1 ipsilateral, 1.9 6 0.4 contralateral, from naive
levels of 1.0; LIF/GAPDH 6 SEM; n 5 4; 6 hr after CFA).
Inflammation in LIF knock-out mice
To directly test whether LIF is required for either the develop-
ment of or recovery from inflammation, we studied the effects of
CFA injection in LIF knock-out mice. The general appearance
and behavior of WT and LIF knock-out mice are quite similar,
although the latter are slightly smaller (Stewart et al., 1992).
There is, however, a very significant difference in the response of
the two strains to CFA injection. Four hours after CFA admin-
istration, the hindpaws in the mutant mice were swollen on the
entire dorsal and plantar surfaces, which differed with the degree
Figure 1. Several measures of inflammation after injection of CFA are
strongly enhanced in LIF knock-out mice. The LIF knock-out mice
display a significantly greater elevation of both IL-1b and NGF than the
WT mice ( p , 0.05; n 5 5). IL-1b and NGF levels measured by ELISA
are expressed as the ratio of the values obtained from the ipsilateral paw
over the contralateral paw. Both WT (1/1) and LIF null mutant (2/2)
mice were examined 48 hr after CFA injection in the ipsilateral paw.
Swelling is expressed as the change in the dorsoventral paw diameter
value from preinflamed levels in WT (1/1) and LIF (2/2) null mutant
mice. The percent increase in the mutant mouse was substantially greater
( p , 0.01, Mann–Whitney U test) than in the WT mice. n 5 12 for naive
and WT; n 5 6 for all other groups.
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of swelling in WT mice, which at this time point was restricted to
the site of the injection. At 24 and 48 hr the swelling spread past
the ankle and up the calf, and the entire plantar and dorsal skin
of the foot was under marked tension and edematous. In WT
littermates at these time points, inflammation was limited to the
hindpaw, and even here it was much less prominent than in the
2/2 mice. The difference in dorsoventral paw diameter at 48 hr
after CFA injection was quantified for the two strains and is
presented in Figure 1. The mean percentage increase in paw
diameter is more than twice as great in the LIF knock-out mice
compared with WT mice ( p , 0.01). Because the degree of
swelling in the 2/2 mice was associated with a marked changes in
the tension, compliance, fluid content, and thickness of the skin,
a meaningful comparison of mechanical and thermal sensitivity
between WT and 2/2 mice was not possible.
Another assay for inflammation involves quantification of cy-
tokines and growth factors that are elevated under a variety of
inflammatory conditions (Woolf et al., 1994, 1996; Safieh-
Garabedian et al., 1995). We found that CFA injection induced a
twofold elevation in IL-1b at 24 hr in WT mice (from naive levels
of 564 6 27 pg/hindpaw to 1068 6 63 pg/ipsilateral hindpaw and
526 6 21 pg/contralateral hindpaw; n 5 5). In LIF knock-out
mice, however, the IL-1b levels at 48 hr after CFA were 1712 6
364 pg/ipsilateral hindpaw and 226 6 53 pg/contralateral hind-
paw; (n 5 5). When the data are expressed as a ratio of the levels
in the inflamed (ipsilateral) to noninflamed (contralateral) hind-
paws at 48 hr, CFA induces a twofold rise in IL-1b in the WT
mice and a ninefold rise in the mutant mice (Fig. 1). A similar
difference was detected for NGF levels in the hindpaw, with a
significantly greater ratio in mutant versus WT animals (Fig. 1).
At 48 hr, NGF levels in WT mice were 94.6 6 10 pg/ipsilateral
hindpaw and 40.8 6 12.8 pg/contralateral hindpaw (n 5 5),
whereas in mutant mice the levels were 186 6 46 pg/ipsilateral
hindpaw and 49.3 6 21 pg/contralateral hindpaw; (n 5 5).
Analysis of the thickness and cellular infiltrates in WT and LIF
mutant mice reinforced these findings. Staining of skin sections
48 hr after CFA revealed not only a much thicker dermis in the
mutants, but many more densely stained neutrophils (Fig. 2). This
difference was quantified by counting cells in nine sections from
three animals of each genotype. The LIF mutant mice had
4.8-fold more neutrophils in the inflamed dermis than WT litter-
mates (1/1, 40.2 6 7.1; 2/2, 190.0 6 15.1; n 5 9). When
expressed as neutrophil density (per 100 mm2), the mutants had
more than twice as many cells as the WT mice (1/1, 8.6 6 0.2;
2/2, 20.8 6 1.5; p , 0.005). The mutants also had greater than
twofold more mast cells than the WT mice.
Figure 2. Adjuvant-induced inflammation produces
a greater immune cell infiltration in LIF mutant
(2/2) than in WT (1/1) mice. Hematoxylin and
eosin staining of the footpad skin, 48 hr after CFA
injection, reveals a much thicker dermis (top) in the
2/2 compared with 1/1 mice. Bottom panels reveal
that this difference is attributable to more polymor-
phonuclear neutrophils (arrowhead) in the dermis of
2/2 compared with 1/1 mice. Scale bar: top panels;
200 mm; bottom panels, 20 mm.
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Effects of exogenous LIF
The greater inflammatory response to CFA in mice lacking LIF
suggests an anti-inflammatory role for this cytokine. To test this
directly, we injected LIF into the rat hindpaw 10 min before CFA
injection. Injection of 10 ng of LIF into the hindpaw (spread over
plantar and dorsal surfaces) had no detectable effect on CFA-
induced inflammation, as measured by behavioral sensitivity, paw
diameter, NGF, and IL-1b levels (n 5 5; data not shown).
Hindpaw injection of 100 ng of LIF before CFA did, however,
have a marked effect. Both mechanical and thermal sensitivity in
the early phase of inflammation were substantially reduced (Fig.
3). Maximal LIF-induced analgesia in both assays was observed 3
hr after CFA injection ( p , 0.001). An effect of LIF on thermal
sensitivity was also apparent at 48 hr ( p , 0.01). Thus, injection
of LIF at a single time point has significant consequences for the
subsequent rate and extent of pain associated with inflammation.
The timing of the injection was important. In rats with preestab-
lished CFA-induced inflammation (48 hr), injection of 100 ng of
LIF into the inflamed hindpaw failed to modify the mechanical or
thermal sensitivity tested 1, 3, and 6 hr after the LIF injections;
(n 5 5; data not shown).
LIF injections at 50 and 100 ng had little effect on baseline
mechanical or thermal sensitivity in the absence of inflammation
(Fig. 4), but at 500 ng a significant thermal hyperalgesia was
present 3 and 6 hr after the high-dose injection (Fig. 4).
Consistent with its analgesic effects, LIF injection reduced the
induction of IL-1b and NGF stimulated by CFA (Fig. 5). Injection
of LIF did not, however, suppress paw swelling; 3 hr after CFA
treatment, the dorsoventral paw diameter increased by 28 6 6%
(n 5 4), whereas in the LIF (100 ng) 1 CFA group this increase
was 25 6 4% (n 5 4), even though there was reduced hypersen-
Figure 3. Administration of LIF to the paw reduces and/or delays the
mechanical and thermal hypersensitivity caused by CFA. LIF (100 ng
total) was injected into the plantar and dorsal surfaces of the hindpaw 10
min before CFA injection, and the sensitivity to mechanical and thermal
stimuli was measured as described in Materials and Methods. Thermal
hyperalgesia at 1 and 3 hr is significantly reduced by LIF (***p , 0.001),
and the difference is maintained at 48 hr (**p , 0.01). Mechanical
sensitivity, which begins to appear at 3 hr, is also attenuated at that time
(***p , 0.001). n 5 6 for each data point.
Figure 4. Intraplantar injection of LIF at 50, 100, and 500 ng into the
paw of noninflamed rats failed to modify mechanical sensitivity. The
highest dose (500 ng) did, however, significantly decrease thermal re-
sponse latency at 3 and 6 hr after injection (*p ,0.05; **p , 0.01). n 5 4
for each data point.
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sitivity at this time. No difference in paw diameter was detected
in these animals 24 and 48 hr after CFA alone or CFA with 100
ng of LIF.
DISCUSSION
Inflammation is a complex, multifactoral process involving cell
infiltration, release of cytokines, growth factors, and inflamma-
tory mediators by inflammatory and damaged cells, as well as
altered blood flow, capillary permeability, and changes in pain
sensitivity (Liles and van Voorhis, 1995; Watkins et al., 1995;
Dinarello, 1996). A challenge is to try to identify which signal
molecules produced during inflammation directly or indirectly act
on sensory neurons. Although much emphasis has been rightly
placed on the sequence of changes that generate inflammatory
pain hypersensitivity, it is clear that compensatory mechanisms
suppressing inflammation and pain may also be recruited during
and after the initial insult. Our data indicate that LIF is a major,
anti-inflammatory molecule produced during cutaneous inflam-
mation. That is, the absence of endogenous LIF leads to a large
potentiation of the inflammatory response, and raising LIF levels
through a single injection counters several of the acute effects
of CFA.
Inflammatory edema has both neurogenic and non-neurogenic
components, the latter being the consequence of the direct action
of inflammatory mediators on the vasculature and capillary per-
meability, whereas the former are attributable to an efferent
function of sensory neurons releasing vasoactive neuropeptides as
part of the axon reflex (Barnes, 1996; Lynn et al., 1996). Although
it is not clear which component is exaggerated in the LIF knock-
out mice, the failure of exogenous LIF to reduce swelling while
diminishing IL-1b and NGF levels indicates an early divergence
of the inflammatory pathways involved. This finding suggests that
further investigation of LIF effects on these pathways will prove
fruitful. High doses of LIF (1 mg) are reported to produce
swelling in the goat radiocarpal joint (Carroll et al., 1995), and
injection of .100 ng of LIF directly into the ear pinnae of mice
increases ear thickness, although by a much smaller extent than a
250-fold lower dose of IL-1a (McKenzie et al., 1996). It is
possible that these proinflammatory effects of LIF are attribut-
able to a biphasic dose dependence, such that anti-inflammatory
effects are seen at lower doses. On the other had, the effects of
high concentrations of LIF may be mediated through binding to
receptors for other members of this cytokine family, all of which
use the gp130 signal-transducing subunit (Stahl and Yancopoulos,
1994). The same issues are raised by a report that injection of a
high dose (1 mg) of LIF into noninflamed juvenile rats (12 d old)
induces a prolonged hypersensitivity to mechanical stimulation
(Thompson et al., 1996). We did not observe any effect on
mechanical sensitivity with lower doses of LIF (up to 500 ng) in
footpad injections in noninflamed adult rats. Either the dose or
the age of the animals may account for this difference. We did
find, though, a hyperalgesic action of LIF but only at a high dose
(500 ng). Thus, caution is needed in interpreting the proinflam-
matory effects of high concentrations of exogenous LIF, which
may have pharmacological actions that differ from those of en-
dogenous LIF. This interpretation is supported by our results
with the LIF knock-out animals.
Inflammatory pain is the consequence of changes in the sensi-
tivity of sensory nerve endings (peripheral sensitization), as well
as changes in sensory neuron phenotype and synaptic transmis-
sion in the spinal cord (central sensitization) (Woolf, 1983; Le-
vine and Taiwo, 1994; Reeh, 1994). Multiple inflammatory me-
diators, including bradykinin, hydrogen ions, histamine and other
amines, ATP, and prostaglandins, interact synergistically to in-
crease transduction sensitivity of high-threshold nociceptors by
phosphorylating sodium channels (Gold et al., 1996). It has re-
cently become apparent that inflammation results in the upregu-
lation of NGF (Donnerer et al., 1992) and that this induces
peripheral sensitization by direct and indirect means (Lewin et
al., 1994). NGF induction also modifies the phenotype of TrkA-
expressing nociceptor neurons (Leslie et al., 1995; Neumann et
al., 1996). Neutralization or sequestration of NGF has profound
analgesic actions on experimental inflammation (Lewin et al.,
1994; Woolf et al., 1994; McMahon et al., 1995) whereas admin-
istration of NGF induces pain hypersensitivity (Lewin et al.,
1993). NGF expression during inflammation is the consequence
of upregulation of both IL-1b and tumor necrosis factor a
Figure 5. Intraplantar injection of LIF reduces the inflammation-
induced elevation in IL-1b and NGF 3 hr after CFA administration.
Preadministration of 100 ng of LIF into the plantar and dorsal surfaces of
the hindpaw before CFA injection reduces the elevation in IL-1b levels by
60% and NGF levels by 50%. n 5 4; *p , 0.05 CFA versus naive; #p ,
0.05 CFA 1 100 ng of LIF versus CFA.
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(TNF-a) (Woolf et al., 1996, 1997). The fact that recombinant
LIF suppresses both IL-1b and NGF upregulation after inflam-
mation and that deletion of LIF results in an amplified induction
of these proteins points to a role for LIF in regulating the
cytokine cascade at an early stage. It is noteworthy that LIF
appears to have different actions in chondrocytes in which it
increases IL-1, IL-6, and IL-8 levels (Shimon et al., 1997). Al-
though the cellular target for LIF action in skin remains to be
determined, LIF presumably exerts its anti-inflammatory effect
via the Jak–STAT pathway (Stahl and Yancopoulos, 1994). This
could lead to the blockade of the transcription or release of a
proinflammatory cytokine such as IL-1 (Figs. 1, 5B) or to the
release of an endogenous anti-inflammatory agent such as IL-1
receptor antagonist (Dinarello, 1996). Regarding potential up-
stream activators of LIF, TNF-a induces LIF in dermal cultures
(Campbell et al., 1993).
LIF mediates diverse functions in the developing and adult
organism. Our findings show that LIF can be a protective cyto-
kine, which is induced early during inflammation and which
suppresses the expression of cytokines and growth factors that
contribute to the inflammatory response and pain. These results
suggest the opportunity for development of novel anti-
inflammatory and analgesic targets such as gp130 and LIF recep-
tor agonists.
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